Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% on Friday, putting it on course for its worst-ever daily loss, after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed expectations.The maker of the wildly popular Wegovy obesity drug said its new drug candidate helped patients reduce their weight by 22.7%, below the 25% it had forecast, according to Reuters.The s ...

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one o ...

Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this case an undisclosed cardiometabolic targetTotal potential deal value up to $186M in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales WALTHAM, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Photys Therapeutics, Inc., a proximity-based therapeutics company, today announced a multi-year collaborati ...

Core Viewpoint - There is a potential new side effect associated with Novo Nordisk's diabetes drug Ozempic, linked to an increased risk of a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) in Type 2 diabetes patients [2][3][8]. Group 1: Study Findings - Danish health authorities are requesting a review from the European Union's drug regulator based on findings from two studies that suggest a link between Ozempic and NAION [2]. - The first study analyzed data from over 400,000 diabetes patients, with a quarter using Ozempic, while the second study involved more than 44,000 Danish patients and nearly 17,000 Norwegian patients who used the drug [9]. - Both studies indicated that diabetes patients using Ozempic were more than twice as likely to be diagnosed with NAION compared to those on other diabetes medications [8]. Group 2: Incidence and Risk Assessment - The Danish Medicines Agency reported 19 cases of NAION in Denmark as of December 10, with an increase in overall cases from around 60-70 annually to up to 150 since Ozempic's introduction in 2018 [4][5]. - The absolute risk of developing NAION for patients using semaglutide (Ozempic) is estimated to be low, with a 0.3% to 0.5% chance over 20 years of use [11]. - The authors of the studies noted that while there may be an increased risk, the low number of observed events suggests that any potential risk is likely limited in magnitude [12]. Group 3: Company Response and Market Impact - Novo Nordisk stated that after a thorough evaluation, they believe the benefit-risk profile of semaglutide remains unchanged and emphasized patient safety as a priority [7]. - Analysts are currently not overly concerned about the potential impact of NAION on Ozempic prescriptions, suggesting that unless semaglutide is found to be unique among GLP-1s in harboring this risk, prescribing practices are unlikely to be affected [13][14].

Novo Nordisk (NVO) announced that it plans to invest DKK 8.5 billion, translating to approximately $1.2 billion, to set up a new production facility in Odense, Denmark. Per NVO, the new site will include a state-of-the-art production facility and warehouse covering more than 40,000 m². Designed with modularity and flexibility in mind, it will support the production of various product types for rare diseases, including haemophilia, both now and in the future.Novo Nordisk reported that construction has alread ...

Core Insights - Novo Nordisk plans to invest 8.5 billion Danish kroner to establish a new production facility in Odense, Denmark, marking its first new production site in the country this century [1]. Group 1: Investment and Facility Details - The new facility will cover over 40,000 m² and will be designed to be modular and flexible, accommodating multiple product types for rare diseases, including haemophilia [4]. - Construction has already begun and is expected to be completed by 2027, creating 400 permanent jobs and employing up to 1,000 external workers during the construction phase [6]. Group 2: Environmental Commitment - The facility will incorporate sustainable practices, including the planting of over 4,000 new trees, installation of solar panels for on-site electricity generation, and the reuse of excess materials to create community spaces [5]. Group 3: Company Background - Novo Nordisk is a leading global healthcare company, founded in 1923, with a focus on chronic diseases, particularly diabetes, and operates manufacturing sites in several countries including Denmark, the US, France, Brazil, and China [8][9].

HIGHLIGHTS Novo has strengthened its high-quality, Australian based exploration portfolio by executing binding term sheets relating to TechGen Metals Limited’s (ASX: TG1) (TechGen) John Bull Gold Project in the New England Orogen of NSW, and Manhattan Corporation Limited’s (ASX: MHC) (Manhattan) Tibooburra Gold Project in the Albert Goldfields in northwestern NSW.Both projects demonstrate prospectivity for significant discovery and resource definition and align with Novo’s strategy of identifying and explor ...

Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the label expansion of Ozempic (semaglutide) to treat patients with type II diabetes (T2D) and chronic kidney disease (CKD) in the EU. Subject to approval, the drug will be indicated as an adjunct to the standard of care for the prevention of the progression of renal impairment in T2D and CKD patients. A final decision from EMA is expe ...

Since I last wrote about the leading weight loss treatments company and stock Novo Nordisk A/S ( NVO ) in early October, its share price has softened just a bit, by 3.7%. This was to be expected. I had given the stock a HoldManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the green economy. Her investing group, Green Gro ...

A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Novo Nordisk just got a step closer to significantly improving supply for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.The Danish drugmaker's parent company, Novo Holdings, ...